Literature DB >> 18357369

BIGH3 is overexpressed in clear cell renal cell carcinoma.

Masanori Yamanaka1, Fumihiro Kimura, Yutaka Kagata, Nobuo Kondoh, Tomohiko Asano, Mikio Yamamoto, Masamichi Hayakawa.   

Abstract

To identify new target marker genes in renal cell carcinoma (RCC), we compared the gene expression profiles of clear cell RCC (cc-RCC) and normal kidney tissue using serial analysis of gene expression. Our results revealed that the transforming growth factor beta induced 68 kDa protein (TGF-betaI: beta ig-h3 (BIGH3), plasminogen activator inhibitor-1 (PAI-1) and transforming growth factor beta1 (TGF-beta1) genes are up-regulated in cc-RCC. To further assess the role of BIGH3 in RCC, we investigated the mRNA expression levels of BIGH3, TGFbeta1, PAI-1 and also of TGF-beta1 related genes in 53 RCC and 30 normal kidney tissues by quantitative real-time RT-PCR (QRT-PCR). We further determined the BIGH3 protein levels in 52 cc-RCC paraffin-embedded tissue samples by immunohistochemistry. BIGH3 mRNA was found to be highly overexpressed in cc-RCC compared with normal tissues with an average ratio of 27. The mRNA levels of TGF-beta1 and PAI-1 were also detected at significantly elevated levels in these cancers. Immunohistochemical analysis of BIGH3 also revealed strong staining in the majority of the cc-RCC samples. In addition, the up-regulation of BIGH3 and PAI-1 was found to correlate with the clinicopathological parameters associated with a poorer patient outcome, whereas TGF-beta1 expression was determined to be unrelated to cancer progression. Strong BIGH3 staining thus tended to be associated with a poor prognosis. BIGH3 was also induced in some RCC cell lines by TGF-beta1 stimulation and this correlated well with PAI-1 up-regulation, suggesting that these enhancements are regulated by a similar mechanism in these tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18357369

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  10 in total

Review 1.  Mechanism of radiation carcinogenesis: role of the TGFBI gene and the inflammatory signaling cascade.

Authors:  Tom K Hei; Yongliang Zhao; Hongning Zhou; Vladimir Ivanov
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

2.  ß3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells.

Authors:  David A Tumbarello; Jillian Temple; James D Brenton
Journal:  Mol Cancer       Date:  2012-05-28       Impact factor: 27.401

Review 3.  Evolving cancer-niche interactions and therapeutic targets during bone metastasis.

Authors:  Robert L Satcher; Xiang H-F Zhang
Journal:  Nat Rev Cancer       Date:  2021-10-05       Impact factor: 69.800

4.  Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma.

Authors:  Chandraiah Godugu; Ravi Doddapaneni; Apurva R Patel; Rakesh Singh; Roger Mercer; Mandip Singh
Journal:  Pharm Res       Date:  2015-08-19       Impact factor: 4.200

5.  TGFBI is involved in the formation of polyploid cancer cells and the response to paclitaxel.

Authors:  Xiaobin Shang; Bibo Yuan; Jingjing Li; Fangfang Xi; Jingxin Mao; Chen Zhang; Hongjing Jiang; Guoyan Liu
Journal:  Ann Transl Med       Date:  2021-04

6.  The role of TGFBI in mesothelioma and breast cancer: association with tumor suppression.

Authors:  Bingyan Li; Gengyun Wen; Yongliang Zhao; Jian Tong; Tom K Hei
Journal:  BMC Cancer       Date:  2012-06-13       Impact factor: 4.430

7.  Identification and characterization of transforming growth factor beta-induced in circulating tumor cell subline from pancreatic cancer cell line.

Authors:  Taku Sato; Tomoki Muramatsu; Minoru Tanabe; Johji Inazawa
Journal:  Cancer Sci       Date:  2018-09-21       Impact factor: 6.716

Review 8.  Transforming growth Factor-Beta-Induced Protein (TGFBI)/(βig-H3): a matrix protein with dual functions in ovarian cancer.

Authors:  Miranda P Ween; Martin K Oehler; Carmela Ricciardelli
Journal:  Int J Mol Sci       Date:  2012-08-21       Impact factor: 6.208

Review 9.  The role of quantitative mass spectrometry in the discovery of pancreatic cancer biomarkers for translational science.

Authors:  Daniel Ansari; Linus Aronsson; Agata Sasor; Charlotte Welinder; Melinda Rezeli; György Marko-Varga; Roland Andersson
Journal:  J Transl Med       Date:  2014-04-05       Impact factor: 5.531

10.  BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation.

Authors:  Tianhong Pan; Song-Chang Lin; Kai-Jie Yu; Guoyu Yu; Jian H Song; Valerae O Lewis; Justin E Bird; Bryan Moon; Patrick P Lin; Nizar M Tannir; Eric Jonasch; Christopher G Wood; Gary E Gallick; Li-Yuan Yu-Lee; Sue-Hwa Lin; Robert L Satcher
Journal:  Neoplasia       Date:  2017-11-27       Impact factor: 5.715

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.